particularly concentrated on the predicted relationship between the plasma level of NT and the therapeutic effect.
The clinical efficacy of the TAs is established beyond doubt (Bennet 1967) , but the therapeutic effect varies considerably among patients and between studies. This is the main problem in the therapeutic use of these drugs. Consequently, rational treatment strategies are urgently required, particularly since the time-lag between the onset of treatment and the onset of therapeutic effect may sometimes span several weeks. Thus, valuable time will be lost by a trial-anderror type of therapy.
Several investigators have performed controlled trials in order to compare different TAs, but no clear-cut and consistent clinical differences have emerged between the various compounds. Dosage hqs been given little attention by these investigators. I shall briefly deal with this problem in the context of endogenous depression and in the view of our knowledge of the kinetics of NT.
The usual recommended doses are modest by comparison with their chemical cousins, the phenothiazines. However, some authors have suggested the need for high doses of about 300 mg per day for an optimal result. When sufficiently sensitive analytical methods became available for the assay of TA in plasma a consistent and substantial variability in drug plasma levels between individuals on the same dosage became apparent , Hammer & Sjoqvist 1967 . The natural question is, therefore: Can the variations in clinical results be explained by the differences in the plasma levels of the drug? Using NT, the monomethylated congener of amitriptyline as an example, I shall try to summarize some clinical-pharmacological efforts made to elucidate these problems.
The first condition of a meaningful correlation between the plasma concentration of a drug and its clinical effect is that the kinetic behaviour of the drug is thoroughly investigated. The pharmacokinetics of NT have been intensely studied by Alexanderson and coworkers (Alexanderson & Sjoqvist 1973) , in a series of investigations in healthy volunteers. In this respect NT is the best known of all antidepressant drugs. The absorption, the binding and the distribution as well as the metabolism are now well elucidated. The data indicate that during continuous medication the plasma concentration is determined mostly by the rate of metabolism. It is known that NT lacks major psychoactive metabolites, an obvious advantage when plasma levels are related to clinical effects. This is in contrast to dimethylated compounds such as amitriptyline and imipramine. From these drugs metabolites are formed, which in themselves are active compounds, and since the ratio of parent compound to the metabolite varies between individuals, interpretation of the relationship between drug and metabolite levels on one side and the clinical outcome on the other side becomes complicated. The steady-state plasma level of NT during prolonged administration is a reproducible individual characteristic, governed by genetic as well as environmental factors (Alexanderson et al. 1969 , Gram & Over0 1972 . Plasma levels of TAs are measured in nanograms per millilitre, and only with the development of highly sensitive analytical procedures, such as gas chromatography, has it been possible to determine plasma levels in man during therapy.
The same basic design was used in all the clinical studies. After a wash-out period, when the patients received placebo treatment for 4-7 days, NT was started and given for four weeks. The doses were given three times a day at 8 hour intervals. The freedom of patients from antidepressant drugs in plasma at the end of the placebo period was always checked and those who were not free were excluded from the studies. Ratings of side-effects and severity of depression were performed at the end of the placebo period and once a week during active treatment. Nortriptyline concentrations in plasma were determined twice weekly according to the method of Hammer & Brodie (1967) in the first studies, but later by a gas chromatographic assay (Borga & Garle 1972) .
The relationship between plasma concentration of NT and side-effects was investigated by Asberg et al. (1970) . From the study it was concluded:
(1) Side-effects have repeatedly been found to be associated with very high plasma levels of NT. The only alarming side-effects encountered occurred on plasma levels exceeding 200 ng/ml. (2) The estimate of corrected side-effects (i.e. the placebo scores subtracted for each patient from his scores on NT) could be correlated with the plasma level of NT during the first three weeks of treatment, although the correlation coefficient amounted to only 0.50. (3) The dose of NT could not be correlated with the corrected side-effect scores. This finding is of clinical importance because very high plasma levels may be obtained with quite moderate doses.
In the studies concerning the relationship between plasma concentration and therapeutic effect this has been investigated in different stages by our groups. In the first study by Asberg et al. (1971) no linear relationship between the plasma concentration of NT and the therapeutic effect was observed in 32 endogenously depressed patients. It appeared that patients presenting high plasma levels as well as low plasma levels seemed to be poorer responders than the remainder. The best results were obtained at plasma levels between 50 and 140 ng/ml.
This study was certainly open to criticism on the following grounds. The treatment period was only two weeks and the patients were not completely without other drug treatment, since barbiturates were prescribed for night sedation. Also the prerequisites for a proper test of a hypothesis were not fulfilled since the hypothesis tested was derived from inspection of the data.
In view of the obvious weakness of this pilot study a second study was performed at the State Mental Hospital of Glostrup in Copenhagen (Kragh-S0rensen etal. 1973) .
Only patients with moderate or severe endogenous depression were included, and every effort was made to keep the patients in the study for at least four weeks. The general design was similar to that of the pilot study, but the investigation was designed to test the hypothesis of a curvilinear relationship between the plasma concentration and the effect of NT. A therapeutic range was also sought.
The correlation between depression score and plasma level of NT was positive and reached significance at the fourth week, although the correlation coefficient is still quite low (r=0.42). However, it is evident from inspection of the data that the relationship is not rectilinear (Fig 1) . The data are here presented in amelioration scores. The poor therapeutic response to very high plasma concentrations of NT was apparently confirmed in this study. However, the upper limit of the therapeutic concentration range is higher than in the pilot study. From the present data we have suggested an upper therapeutic limit about 170 ng/ml. It should be emphasized that Burrows et al. (1972) , using a similar technique to the pilot study, failed to establish any relationship whatsoever between the NT plasma level and the therapeutic effect.
Several conditions may account for this discrepancy, but there are probably two main explanations: (1) Burrows and coworkers did not differentiate between endogenous depression and other depressions, and also patients with severe depressive illness were excluded. Thus, the patients differed substantially. (2) The fluctuation of plasma concentrations in the Australian investigation was very large. As the basic condition we believe that equilibrium between plasma and receptor compartments must be reached, before any relationship can be made out. In the work of Burrows and coworkers this may not have been obtained.
Our results do not finally prove that our theory is correct, but they do give a reasonable basis for the hypothesis that an upper therapeutic limit in fact exists. We hope that a study now in progress will provide the final answer.
The investigation which is expected to be completed within the next four months,' is controlled in a triple-blind fashion, and the design is quite complicated. The doses as well as the plasma concentration of NT will throughout the period of the investigation remain unknown to the clinical examinators, the hospital department and the patient. Two independent investigators know the plasma levels and control the doses, but are unaware of the clinical evaluation. Prior to the start of the investigation the patients have been allocated at random into two groups.
One group is adjusted to a high NT plasma level ranging from 180 to 200 ng/ml, the other group is adjusted to a plasma concentration around 130 ng/ml, which is inside our postulated therapeutic range. The period of treatment for each patient is one week on placebo followed by four weeks on NT treatment. At the end of this period the high level patients are allocated at random to two groups. One continues on the same dose, the other one on a decreased dose. This design was chosen to evaluate the possible influence ofchange in the plasma level.
Concerning other TAs, Braithwaite et al. a mixed depressive patient sample. They found a strong positive correlation between plasma level and effect. These results are similar to those obtained by Walther (1971) with imipramine. In both these investigations, however, the number of patients with high plasma levels is small! Braithwaite and coworkers found only one patient with a NT level above 175 ng/ml, and again NT was derived from amitriptyline which is in itself an active compound, and strict comparison between the studies is thus impossible.
Another problem in the psychiatric clinic today is the possible value of long-term prophylactic treatment with the TAs. Definite evidence for a prophylactic effect is still lacking. In order to clarify the clinical pharmacological basis for a correct design of controlled trials, we have followed 22 patients from the previous study, all successfully treated with NT (KraghS0rensen et al. 1974).
The treatment was continued up to five months in the outpatient clinic and the plasma levels of NT were regularly checked. The psychiatric state was assessed by ratings. The NT dosage was kept constant during the follow-up period.
During long-term treatment with TA it is important to ascertain that the steady-state plasma concentration obtained after a few weeks of treatment is kept constant during subsequent treatment for months or years. It should be kept in mind that previous investigators have recommended a reduced dose during the follow-up period. However, our results demonstrate that such a reduction is not justified from a pharmacokinetic point of view and probably most inexpedient from a clinical point of view, because of the lower plasma levels obtained thereby (Fig 2) .
We have now followed 10 of these patients for more than a year and their plasma levels are still found to be around the original levels, on the same NT doses. 
Conclusion
The analytical method for the determination of NT in plasma here proved to be highly sensitive and specific. The method has been available for controlled trials and in clinical practice. Concerning the effect of TAs during long-term treatment our investigations have shed light on unclarified dosage factors of great importance for the elucidation of the possible prophylactic effect of the TAs.
The plasma level determination of NT has simplified the discrimination between true pharmacological side effects, which call for reduction of dosage, and placebo or depressive symptoms. In patients not responding to a certain dosage, a plasma level determination will indicate whether the dosage should be raised or rather lowered. Our results prove this point, and we think we have a reasonable basis for the hypothesis that both a lower and an upper limit for therapeutic effect exist.
Next, those patients who do not recover, even on optimal plasma levels, can be identified and receive alternative treatment, instead of undue prolongation of an ineffective therapy on changing doses.
Whether a relationship between the plasma concentration and effects will hold also for other TAs remains to be investigated. It (Svensmark et al. 1960 , Loeser 1961 . It is usually unnecessary to administer the drug more than twice daily; indeed, steady state levels throughout the day have been reported with a single daily dose (Haerer & Buchanan 1972 , Strandjord & Johannessen 1972 . (3) For any individual patient the relationship between dose and serum level is not a linear one, as the latter will rise increasingly steeply as the dose is steadily increased (Bochner et al. 1972a) . Within the optimum range of 10-20,tg/ml small incremental changes of dose may lead to a relatively large rise or fall in serum level, perhaps precipitating toxicity or loss of seizure control. (4) The capacity to metabolize (parahydroxylate) the drug varies with age, especially in children, in whom relatively larger doses (in terms of body weight) are required to achieve serum levels comparable to adult patients (Svensmark & Buchthal 1963 , Jalling et al. 1970 ).
